Your browser doesn't support javascript.
loading
Validation of a prognostic model for predicting larynx preservation outcome (TALK score) in a Southern European population
Marruecos-Querol, Jordi; Vayreda, Jordi; Eraso, Aranzazu; Rubió-Casadevall, Jordi; Lozano, Alicia; Linares, Isabel; Buxó, Maria; Puigdemont, Montserrat; Planas, Isabel; Cirauqui, Beatriz.
Afiliação
  • Marruecos-Querol, Jordi; Catalan Institute of Oncology. Radiation Oncology Department. Girona. Spain
  • Vayreda, Jordi; Catalan Institute of Oncology. Radiation Oncology Department. Girona. Spain
  • Eraso, Aranzazu; Catalan Institute of Oncology. Radiation Oncology Department. Girona. Spain
  • Rubió-Casadevall, Jordi; Catalan Institute of Oncology. Medical Oncology Department. Girona. Spain
  • Lozano, Alicia; Catalan Institute of Oncology. Radiation Oncology Department. L’Hospitalet de Llobregat. Spain
  • Linares, Isabel; Catalan Institute of Oncology. Radiation Oncology Department. L’Hospitalet de Llobregat. Spain
  • Buxó, Maria; Girona Biomedical Research Institute (IDIBGI). Girona. Spain
  • Puigdemont, Montserrat; Catalan Institute of Oncology. IDIBGI. Descriptive Epidemiology, Genetics and Cancer Prevention Group. Girona. Spain
  • Planas, Isabel; Catalan Institute of Oncology. Radiation Oncology Department. Badalona. Spain
  • Cirauqui, Beatriz; Catalan Institute of Oncology. Medical Oncology Department. Badalona. Spain
Clin. transl. oncol. (Print) ; 25(8): 2384-2392, aug. 2023.
Artigo em Inglês | IBECS | ID: ibc-222416
Biblioteca responsável: ES1.1
Localização: ES15.1 - BNCS
ABSTRACT
Objective Larynx preservation is the current standard for locally advanced (LA) laryngeal/hypopharyngeal tumors, but not all patients respond as expected. TALK score model measures four variables (T-staging, albumin levels, liquor consumption and Karnofsky score) to determine which cases are best suited to preservation treatment scheme. We aimed to validate this prognostic model in a Southern European population. Methods We retrospectively evaluated 175 patients diagnosed from July 2008 to December 2015 with LA laryngeal/hypopharyngeal carcinoma and treated with a laryngeal preservation scheme comprising induction chemotherapy followed by concomitant chemotherapy and radiotherapy. We applied the TALK score model to predict larynx preservation rate. Results Of the 175 patients evaluated, 96.6% were men, 98.3% were smokers and 77.1% misused alcohol. Tumors were laryngeal 66.3% vs 33.7% in hypopharynx, and all were either stage III (37.7%) or stage IV (62.3%). TALK prognostic subgroups were good risk 40.0%; intermediate risk 52.5%; and poor risk 7.5%. With a median follow-up of 40.1 months, larynx preservation rate, laryngectomy-free survival and overall survival at 3 years was 84.5%, 63.7% and 68.2%, respectively. Although TALK score was not predictive of 3-year larynx preservation rate (good risk 85.5%; intermediate risk 83.1%; poor risk 91.6%), it was predictive of 3-year overall survival (good risk 81.9%; intermediate risk 62.9%; poor risk 33.5%) and 3-year laryngectomy-free survival (good risk 75.6%; intermediate risk 59.6%; poor risk 30.7%) Conclusion TALK model could predict OS and laryngectomy-free survival, helping clinicians to decide which patients should avoid laryngeal preservation and undergo laryngectomy after diagnosis (AU)
Assuntos

Buscar no Google
Coleções: Bases de dados nacionais / Espanha Base de dados: IBECS Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Neoplasias Laríngeas / Cisplatino Limite: Feminino / Humanos / Masculino Idioma: Inglês Revista: Clin. transl. oncol. (Print) Ano de publicação: 2023 Tipo de documento: Artigo Instituição/País de afiliação: Catalan Institute of Oncology/Spain / Girona Biomedical Research Institute (IDIBGI)/Spain
Buscar no Google
Coleções: Bases de dados nacionais / Espanha Base de dados: IBECS Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Neoplasias Laríngeas / Cisplatino Limite: Feminino / Humanos / Masculino Idioma: Inglês Revista: Clin. transl. oncol. (Print) Ano de publicação: 2023 Tipo de documento: Artigo Instituição/País de afiliação: Catalan Institute of Oncology/Spain / Girona Biomedical Research Institute (IDIBGI)/Spain
...